Optic Neuritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Optic Neuritis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report also reviews key players involved in therapeutic development for Optic Neuritis (Ophthalmology) and features dormant and discontinued projects.

Optic Neuritis Pipeline Drugs Market Segmentation by Targets

The key targets of the Optic Neuritis pipeline drugs market are Deoxycytidine Kinase, Glucocorticoid Receptor, Myelin Associated Glycoprotein, Myelin Oligodendrocyte Glycoprotein, Reticulon 4, Ribonucleoside Diphosphate Reductase, and Serine/Threonine Protein Kinase Sgk2.

Optic Neuritis Pipeline Drugs Market Analysis, by Targets

Optic Neuritis Pipeline Drugs Market Analysis, by Targets

For more Optic Neuritis pipeline drugs market target insights, download a free report sample

Optic Neuritis Pipeline Drugs Market Segmentation by Mechanism of Actions

The key mechanism of actions of the Optic Neuritis pipeline drugs market are Deoxycytidine Kinase Inhibitor, Glucocorticoid Receptor Agonist, Myelin Associated Glycoprotein Inhibitor, Myelin Oligodendrocyte Glycoprotein Inhibitor, Reticulon 4 Inhibitor, Ribonucleoside Diphosphate Reductase Inhibitor, and Serine/Threonine Protein Kinase Sgk2 Activator.

Optic Neuritis Pipeline Drugs Market Analysis, by Mechanism of Actions

Optic Neuritis Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the Optic Neuritis pipeline drugs market, download a free report sample

Optic Neuritis Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Optic Neuritis pipeline drugs market are oral, intravenous, topical, buccal, intraocular, nasal, ophthalmic, subcutaneous, and sublingual.

Optic Neuritis Pipeline Drugs Market Analysis, by Routes of Administration

Optic Neuritis Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into Optic Neuritis pipeline drugs market, download a free report sample

Optic Neuritis Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Optic Neuritis pipeline drugs market are small molecule, cell therapy, fusion protein, gene therapy, peptide, protein, and subunit vaccine.

Optic Neuritis Pipeline Drugs Market Analysis, by Molecule Types

Optic Neuritis Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Optic Neuritis pipeline drugs market, download a free report sample

Competitive Landscape

Some of the leading companies in the Optic Neuritis pipeline drugs market are Cresence AS, EnhanX Biopharm Inc, Find Therapeutics Inc, Japan Innovative Therapeutics Inc, Mitochon Pharmaceuticals Inc, Noveome Biotherapeutics Inc, Oculis SA, Parvus Therapeutics Inc, ReNetX Bio, and SanBio Co Ltd.

Optic Neuritis Pipeline Drugs Market Analysis, by Companies

Optic Neuritis Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the Optic Neuritis pipeline drugs market, download a free report sample

Optic Neuritis Pipeline Drugs Market Report Overview

Key Targets Deoxycytidine Kinase, Glucocorticoid Receptor, Myelin Associated Glycoprotein, Myelin Oligodendrocyte Glycoprotein, Reticulon 4, Ribonucleoside Diphosphate Reductase, and Serine/Threonine Protein Kinase Sgk2
Key Mechanism of Actions Deoxycytidine Kinase Inhibitor, Glucocorticoid Receptor Agonist, Myelin Associated Glycoprotein Inhibitor, Myelin Oligodendrocyte Glycoprotein Inhibitor, Reticulon 4 Inhibitor, Ribonucleoside Diphosphate Reductase Inhibitor, and Serine/Threonine Protein Kinase Sgk2 Activator
Key Routes of Administration Oral, Intravenous, Topical, Buccal, Intraocular, Nasal, Ophthalmic, Subcutaneous, and Sublingual
Key Molecule Types Small Molecule, Cell Therapy, Fusion Protein, Gene Therapy, Peptide, Protein, and Subunit Vaccine
Leading Companies Cresence AS, EnhanX Biopharm Inc, Find Therapeutics Inc, Japan Innovative Therapeutics Inc, Mitochon Pharmaceuticals Inc, Noveome Biotherapeutics Inc, Oculis SA, Parvus Therapeutics Inc, ReNetX Bio, and SanBio Co Ltd

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).
  • Reviews of pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Optic Neuritis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Cresence AS
EnhanX Biopharm Inc
Find Therapeutics Inc
Japan Innovative Therapeutics Inc
Mitochon Pharmaceuticals Inc
Noveome Biotherapeutics Inc
Oculis SA
Parvus Therapeutics Inc
ReNetX Bio
SanBio Co Ltd
Trethera Corp
Worphmed Srl

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Optic Neuritis – Overview

Optic Neuritis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Optic Neuritis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Optic Neuritis – Companies Involved in Therapeutics Development

Cresence AS

EnhanX Biopharm Inc

Find Therapeutics Inc

Japan Innovative Therapeutics Inc

Mitochon Pharmaceuticals Inc

Noveome Biotherapeutics Inc

Oculis SA

Parvus Therapeutics Inc

ReNetX Bio

SanBio Co Ltd

Trethera Corp

Worphmed Srl

Optic Neuritis – Drug Profiles

AXER-204 – Drug Profile

Product Description

Mechanism Of Action

History of Events

EGF1-48 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ENX-201 – Drug Profile

Product Description

Mechanism Of Action

Gene Therapies for Glaucoma, Optic Neuritis and Retinitis Pigmentosa – Drug Profile

Product Description

Mechanism Of Action

gypenoside – Drug Profile

Product Description

Mechanism Of Action

History of Events

Innovative Therapy – Drug Profile

Product Description

Mechanism Of Action

History of Events

melatonin – Drug Profile

Product Description

Mechanism Of Action

History of Events

MP-101 – Drug Profile

Product Description

Mechanism Of Action

OCS-05 – Drug Profile

Product Description

Mechanism Of Action

History of Events

OT-1602 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Optic Neuritis – Drug Profile

Product Description

Mechanism Of Action

History of Events

ST-266 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TRE-515 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Vaccine for Optic Neuritis – Drug Profile

Product Description

Mechanism Of Action

Optic Neuritis – Dormant Projects

Optic Neuritis – Discontinued Products

Optic Neuritis – Product Development Milestones

Featured News & Press Releases

Aug 09, 2022: Trethera announces FDA Orphan Drug Designation granted to TRE-515 for the treatment of demyelinating optic neuritis

Oct 21, 2020: Noveome Biotherapeutics announces publication of preclinical results demonstrating the neuroprotective properties of amnion-derived multipotent pCells in spinal cord and retinal ganglion cells

May 15, 2019: Bionure appoints Dr. Lucia Septien as chief medical officer

May 09, 2019: Noveome Biotherapeutics announces publication of further preclinical results supporting the neuroprotective properties of ST266 in retinal ganglion cells

May 07, 2019: Neuroprotection Biotech Bionure Reports Successful Phase 1 Study for Lead Candidate BN201

Oct 09, 2018: Bionure appoints Dr. Laurent Nguyen as CEO

May 16, 2018: Bionure initiates a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom

Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Optic Neuritis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Optic Neuritis – Pipeline by Cresence AS, 2022

Optic Neuritis – Pipeline by EnhanX Biopharm Inc, 2022

Optic Neuritis – Pipeline by Find Therapeutics Inc, 2022

Optic Neuritis – Pipeline by Japan Innovative Therapeutics Inc, 2022

Optic Neuritis – Pipeline by Mitochon Pharmaceuticals Inc, 2022

Optic Neuritis – Pipeline by Noveome Biotherapeutics Inc, 2022

Optic Neuritis – Pipeline by Oculis SA, 2022

Optic Neuritis – Pipeline by Parvus Therapeutics Inc, 2022

Optic Neuritis – Pipeline by ReNetX Bio, 2022

Optic Neuritis – Pipeline by SanBio Co Ltd, 2022

Optic Neuritis – Pipeline by Trethera Corp, 2022

Optic Neuritis – Pipeline by Worphmed Srl, 2022

Optic Neuritis – Dormant Projects, 2022

Optic Neuritis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Optic Neuritis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Optic Neuritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Optic Neuritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Optic Neuritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Optic Neuritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.